Home › Gilead Announces Results from Phase 2 Study Showing Reduction in...
 

Keywords :   


Gilead Announces Results from Phase 2 Study Showing Reduction in...

2014-05-11 00:54:46| Biotech - Topix.net

Gilead Sciences, Inc. today announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden in patients with paroxysmal atrial fibrillation .

Tags: in results showing study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Farm Progress America, July 3, 2024
03.07Farm Progress America, July 3, 2024
03.07Hurricane Beryl Forecast Discussion Number 19
03.07Hurricane Beryl Wind Speed Probabilities Number 19
03.07Hurricane Beryl Public Advisory Number 19
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Hurricane Beryl Forecast Advisory Number 19
More »